Mirum Pharmaceuticals, Inc.
MIRM
Kedudukan dalam Saham
#3276
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Harga Saham
$82.58
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$5.36B
Perubahan (1 hari)
3.05%
Perubahan (1 tahun)
13.08%
Negara
US
Perdagangan Mirum Pharmaceuticals, Inc. (MIRM)
Kategori
Healthcare
Pendapatan untuk Mirum Pharmaceuticals, Inc. (MIRM)
Pendapatan pada Jun 2026 TTM: $-857.54M
Menurut laporan kewangan terkini Mirum Pharmaceuticals, Inc., pendapatan semasa syarikat ialah $-857.54M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-162.42M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-142.07M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Mirum Pharmaceuticals, Inc. dari 2018 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-857.54M | 886.67% |
| 2024 | $-86.91M | -46.49% |
| 2023 | $-162.42M | 14.33% |
| 2022 | $-142.07M | 69.23% |
| 2021 | $-83.95M | -18.70% |
| 2020 | $-103.26M | 96.57% |
| 2019 | $-52.53M | 202.81% |
| 2018 | $-17.35M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -715.12% |
US
|
|
| $-3.09B | 259.98% |
US
|
|
| $-4.02B | 368.34% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -327.47% |
NL
|
